drugset / Trial / NCT00616005
Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Objective: To determine activity of combo of Irinotecan + Temozolomide To further characterize any toxicity associated w combo of Irinotecan + Temozolomide
Timeline
- Start
- 2005-11
- Primary completion
- 2007-07
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 125 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 325 mg/m2 | Intravenous |
| Subject | Temozolomide | Small molecule | 200 mg/m2 | Oral |